These findings uncovered the master TF regulating the cell identity, supporting that converting BLBC into ERα‐positive breast cancers by targeting POU4F1 is a therapeutically actionable approach for BLBC patients, even TNBC patients. This evidence concerns the gene TF and breast carcinoma.